A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Status:	Archived
Conditions:	Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	October 2010

A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

This is a single-arm, multicenter, Phase Ib study designed to describe the effect of
GDC-0449 on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with
advanced solid tumors who are refractory to treatment or for whom no standard therapy
exists.

We found this trial at

sites

Norwalk Hospital

Norwalk, Connecticut 06856

from

Norwalk, CT